Medical management of hypertrophic cardiomyopathy.

摘要: Hypertrophic cardiomyopathy (HCM) is the most common genetically transmitted cardiomyopathy. The underlying cause of HCM has been attributed to a number mutations within genes encoding primarily for sarcomeric proteins, which lead heterogeneous phenotype left ventricular hypertrophy in absence other causes (eg, hypertension, aortic stenosis, or discrete membranous subaortic stenosis). Symptoms may range from mild severely limiting and consist dyspnea chest pain with exertion at rest, syncope, even sudden cardiac death (SCD). majority patients are treated medically. primary aim therapy reduce symptoms, but it should also address risk SCD. Throughout years, numerous medical treatments have used achieve symptom control these patients, include medications such as β-blockers, calcium channel blockers, amiodarone, disopyramide, angiotensin receptor blockers. This review provides an overview current treatment HCM.